nms-03305293
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 25, 2019 (NCT04182516)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Poly [ADP-ribose] polymerase 4INHIBITOR
PARP4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06930755 | Phase 1 | Dec 31, 2025 | Nerviano Medical Sciences |
| NCT06931626 | Phase 1 | Aug 15, 2025 | Nerviano Medical Sciences |
| NCT04910022 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2021 | Nerviano Medical Sciences |
| NCT04182516 | Phase 1 | Nov 25, 2019 | Istituto Oncologico Veneto IRCCS, Nerviano Medical Sciences |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nerviano Medical Sciences | For profit | 4 | 4 | 2 | 2019 |
| Istituto Oncologico Veneto IRCCS | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1